DrugPatentWatch Database Preview
Drugs in Development Information for BC-3781
» See Plans and Pricing
What is the development status for investigational drug BC-3781?
BC-3781 is an investigational drug.
There have been 4 clinical trials for BC-3781.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2016.
The most common disease conditions in clinical trials are Pneumonia, Pneumonia, Bacterial, and Infection. The leading clinical trial sponsors are Nabriva Therapeutics AG and [disabled in preview].
There are five US patents protecting this investigational drug and one hundred and thirteen international patents.
Summary for BC-3781
| US Patents | 5 |
| International Patents | 113 |
| US Patent Applications | 4 |
| WIPO Patent Applications | 3 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2016-04-01) |
| Vendors | 6 |
Recent Clinical Trials for BC-3781
| Title | Sponsor | Phase |
|---|---|---|
| Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia | Nabriva Therapeutics AG | Phase 3 |
| Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia | Nabriva Therapeutics AG | Phase 3 |
| Bioavailability and Pharmacokinetics of Lefamulin When Administered to Fed and Fasted Healthy Subjects | Nabriva Therapeutics AG | Phase 1 |
Clinical Trial Summary for BC-3781
Top disease conditions for BC-3781
Top clinical trial sponsors for BC-3781
US Patents for BC-3781
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| BC-3781 | Start Trial | Crystal structure of the large ribosomal subunit from S. aureus | Yeda Research and Development Co. Ltd. (Rehovot, IL) | Start Trial |
| BC-3781 | Start Trial | Pleuromutilin derivatives having antibacterial activity | Biochemie Gesellschaft m.b.H. (Kundl, AT) | Start Trial |
| BC-3781 | Start Trial | Pleuromutilin derivatives for the treatment of diseases mediated by microbes | Nabriva Therapeutics AG (Vienna, AT) | Start Trial |
| BC-3781 | Start Trial | Pleuromutilin derivatives for the treatment of diseases mediated by microbes | Nabriva Therapeutics AG (Vienna, AT) | Start Trial |
| BC-3781 | Start Trial | Process for the preparation of pleuromutilins | NABRIVA THERAPEUTICS AG (Vienna, AT) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for BC-3781
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| BC-3781 | European Patent Office | 3250585 | 2035-01-29 | Start Trial |
| BC-3781 | World Intellectual Property Organization (WIPO) | 2016120868 | 2035-01-29 | Start Trial |
| BC-3781 | Argentina | 029590 | 2020-07-11 | Start Trial |
| BC-3781 | Austria | 408596 | 2020-07-11 | Start Trial |
| BC-3781 | Australia | 2001276389 | 2020-07-11 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
